1. Home
  2. Press release
May 17, 2019 16:34 JST

Source: Eisai

"Science Based Targets (SBT) Initiative" Approves Eisai's Greenhouse Gas Reduction Targets


TOKYO, May 17, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai has received approval from "Science Based Targets (SBT) Initiative" for Eisai's mid and long-term targets for greenhouse gas (GHG) reduction.

"SBT Initiative" is an international joint initiative by CDP which is an international NGO operating information disclosure program related to the environment field, the UN Global Compact (UNGC), the World Wildlife Fund (WWF), and the World Resources Institute (WRI). Paris Agreement includes to keep the global average temperature rise since pre-industrial revolution to below 2degC as a long-term common global goal for GHG reduction. According to this adaptation of Paris Agreement, SBT Initiative certifies companies with ambitious targets meeting the SBT "2degC target". "SBT Initiative" certified that the following Eisai's GHG emission reduction targets are recognized as based on scientific grounds and therefore approved.

- 30% reduction of GHG emission (Scope 1 and 2) by FY2030 from FY2016
- 30% reduction of GHG emission (emission based on purchased products and services in Scope 3) by FY2030 from FY2016

Scope 1: Direct emission of GHG released into the air by the use of fossil fuel
Scope 2: Indirect emission of GHG with use of electricity and steam purchased from others
Scope 3: Indirect emission of GHG by supply chain excluding Eisai

Eisai's corporate philosophy is to give first thought to patients and their families, and increase that health care provides as well as address diverse healthcare needs worldwide. Based on this human health care (hhc) philosophy, Eisai will strengthen the activities for climate changes and contributes to ensure the society sustainability.


About Eisai
Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Eisai Launches New Insomnia Drug Dayvigo (Lemborexant) CIV in the United States as a Treatment Option for Adults With Insomnia
June 02 2020 10:05 JST
 
AbbVie and Eisai Announce an Approval for Partial Changes in the Marketing Approval of HUMIRA, a Fully Human Anti-TNFalpha Monoclonal Antibody
May 29 2020 14:54 JST
 
Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials
May 29 2020 10:31 JST
 
Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules
May 18 2020 12:33 JST
 
Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting
May 14 2020 08:22 JST
 
Eisai Selected as Most Honored Company and the First Place of the Sector in "The All-Japan Executive Team (Best IR Company Ranking)" by Institutional Investor Magazine
April 27 2020 16:26 JST
 
Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China
April 01 2020 15:23 JST
 
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)
March 26 2020 16:01 JST
 
Eisai's Discovery Research on Multikinase Inhibitor Lenvatinib Honored with PSJ Award for Drug Research and Development '20
March 25 2020 08:38 JST
 
Eisai to Launch Digital Tool "NouknowTM" in Japan for Regular Self-Assessment of Brain Performance (Brain Health)
March 23 2020 10:53 JST
 
More Press release >>

Latest Press Release


Mitsubishi Corporation and NTT complete investment in HERE Technologies
Jun 02, 2020 14:54 JST

Toyota Announces its Line-up for the New GR Yaris in Japan
Jun 02, 2020 13:35 JST

Eisai Launches New Insomnia Drug Dayvigo (Lemborexant) CIV in the United States as a Treatment Option for Adults With Insomnia
Jun 02, 2020 11:05 JST

MHI RJ Aviation Group Launches as Mitsubishi Heavy Industries Ltd. Closes Acquisition of CRJ Series Program From Bombardier Inc.
Jun 02, 2020 10:23 JST

LEXUS previews the New IS
Jun 02, 2020 09:12 JST

DENSO and Certhon Establish DENSO AgriTech Solutions
Jun 01, 2020 12:48 JST

Fujitsu Signs Partnership Agreement with Scaled Agile, Inc., Driving Large-Scale Agile for Digital Transformation
Jun 01, 2020 12:01 JST

AbbVie and Eisai Announce an Approval for Partial Changes in the Marketing Approval of HUMIRA, a Fully Human Anti-TNFalpha Monoclonal Antibody
May 29, 2020 15:54 JST

Sharp Releases Notice of Corporate Spin-Off of the Display Device Business Division
May 29, 2020 15:47 JST

DENSO Announces Changes in the Areas of Responsibility of Senior Executive Officers and Executive Officers
May 29, 2020 12:05 JST

Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials
May 29, 2020 11:31 JST

Hitachi Announces Change in the Effective Date for Company Split and Closing Date of Share Transfer
May 28, 2020 19:18 JST

Mitsubishi Motors Announces Production, Sales and Export Figures for April 2020
May 28, 2020 19:09 JST

Honda Sets Monthly Records for Automobile Production in China
May 28, 2020 18:52 JST

Mazda Production and Sales Results for April 2020
May 28, 2020 16:46 JST

Mazda Joins IP Open Access Declaration Against Covid-19
May 28, 2020 16:28 JST

Toyota Releases Sales, Production, and Export Results for April 2020
May 28, 2020 13:56 JST

Fujitsu Accelerates Digital Transformation with Flexible, Scale-out Software-Defined Storage ETERNUS Data Services Platform
May 28, 2020 11:26 JST

Alliance New Cooperation Business Model to Support Member-Company Competitiveness and Profitability
May 27, 2020 18:28 JST

eK X and eK Wagon Achieve Top Ratings for Preventive and Collision Safety Performance in JNCAP
May 27, 2020 15:31 JST
 More Latest Release >>